-
公开(公告)号：US20160016940A1
公开(公告)日：2016-01-21
申请号：US14773954
申请日：2013-09-24
Applicant: PFIZER INC.
Inventor： Samit Kumar Bhattacharya , Kimberly O'Keefe Cameron , Matthew Scott Dowling , David Christopher Ebner , David James Edmonds , Dilinie Prasadhini Fernando , Kevin James Filipski , Daniel Wei-Shung Kung , Esther Cheng Yin Lee , Aaron Christopher Smith , Meihua Mike Tu
IPC: C07D405/12 , C07D401/12 , C07D403/12 , C07D401/04
CPC classification number: C07D405/12 , A61K31/4439 , C07D401/04 , C07D401/12 , C07D403/12
Abstract: The present invention relates to indole and indazole compounds of Formula (I) that activate 5′ adenosine monophosphate-activated protein kinase (AMPK). The invention also encompasses pharmaceutical compositions containing these compounds and methods for treating or preventing diseases, conditions, or disorders ameliorated by activation of AMPK.
Abstract translation: 本发明涉及活化5'腺苷单磷酸活化蛋白激酶（AMPK）的式（I）的吲哚和吲唑化合物。 本发明还包括含有这些化合物的药物组合物和用于治疗或预防通过AMPK活化改善的疾病，病症或障碍的方法。
-
公开(公告)号：US20240059679A1
公开(公告)日：2024-02-22
申请号：US18483311
申请日：2023-10-09
Applicant: Pfizer Inc.
Inventor： Gary Erik Aspnes , Scott W. Bagley , John M. Curto , David James Edmonds , Mark E. Flanagan , Kentaro Futatsugi , David A. Griffith , Kim Huard , Yajing Lian , Chris Limberakis , Allyn T. Londregan , Alan M. Mathiowetz , David W. Piotrowski , Roger B. Ruggeri
IPC: C07D405/12 , C07C53/06 , C07C53/10 , C07C215/40 , C07D405/14 , C07D413/14 , C07D471/04
CPC classification number: C07D405/12 , C07C53/06 , C07C53/10 , C07C215/40 , C07D405/14 , C07D413/14 , C07D471/04 , C07B2200/13
Abstract: Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, and 7-aza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
-
公开(公告)号：US20220387402A1
公开(公告)日：2022-12-08
申请号：US17612672
申请日：2020-05-15
Applicant: Pfizer Inc.
Inventor： Gary E. Aspnes , Scott W. Bagley , John M. Curto , Matthew Dowling , David James Edmonds , Dilinie Fernando , Mark E. Flanagan , Kentaro Futatsugi , David Andrew Griffith , Kim Huard , Gajendra Ingle , Wenhua Jiao , Shawn M. LaCasse , Yajing Lian , Chris Limberakis , Allyn T. Londregan , Alan M. Mathiowetz , David Walter Piotrowski , Roger B. Ruggeri , Kristin Wiglesworth
IPC: A61K31/438 , A61K31/496 , A61K31/4545 , A61K31/454 , A61K31/5377 , A61K31/506 , A61K31/46 , A61K45/06 , A61K38/26 , A61K38/28 , A61K38/17 , A61P1/16
Abstract: In part, the invention provides a new combination comprising (1) a GLP-1R agonist and (2) an ACC inhibitor or a DGAT2 inhibitor, or a KHK inhibitor or FXR agonist. The invention further provides new methods for treating diseases and disorders, for example, fatty liver, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, nonalcoholic steatohepatitis with liver fibrosis, nonalcoholic steatohepotitis with cirrhosis, and nonalcoholic steatohepatitis with cirrhosis and with hepatocellular carcinoma or with a metabolic-related disease, obesity, and type 2 diabetes, for example, using the new combination described herein.
-
公开(公告)号：US11065249B2
公开(公告)日：2021-07-20
申请号：US17090619
申请日：2020-11-05
Applicant: Pfizer Inc.
Inventor： David James Edmonds , Kevin James Filipski , Kentaro Futatsugi , Michelle Renee Garnsey , Jack Chang Hung Lee , Daniel Jonathan Smaltz
IPC: A61K31/506 , A61P3/06 , A61K31/155 , A61K31/4545 , A61K31/4985 , A61K31/7048 , A61K45/06 , C07D401/14
Abstract: Described herein are compounds of Formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are defined herein, their use as diacylglycerol acyltransferase 2 (DGAT2) inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, NASH.
-
公开(公告)号：US20190382387A1
公开(公告)日：2019-12-19
申请号：US16535553
申请日：2019-08-08
Applicant: Pfizer Inc.
Inventor： Gary Erik Aspnes , Scott W. Bagley , John M. Curto , David James Edmonds , Mark E. Flanagan , Kentaro Futatsugi , David A. Griffith , Kim Huard , Yajing Lian , Chris Limberakis , Allyn T. Londregan , Alan M. Mathiowetz , David W. Piotrowski , Roger B. Ruggeri
IPC: C07D405/12 , C07D405/14 , C07C53/10 , C07D471/04 , C07C215/40 , C07C53/06 , C07D413/14
Abstract: Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, and 7-aza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
-
Patent Agency Ranking
公开(公告)号：US09394285B2
公开(公告)日：2016-07-19
申请号：US14773954
申请日：2013-09-24
Applicant: Pfizer Inc.
Inventor： Samit Kumar Bhattacharya , Kimberly O'Keefe Cameron , Matthew Scott Dowling , David Christopher Ebner , David James Edmonds , Dilinie Prasadhini Fernando , Kevin James Filipski , Daniel Wei-Shung Kung , Esther Cheng Yin Lee , Aaron Christopher Smith , Meihua Mike Tu
IPC: C07D405/12 , C07D403/12 , C07D401/04 , C07D401/12 , A61K31/404 , A61K31/4439 , A61K31/454 , A61K31/496 , A61P13/12 , A61P3/10
CPC classification number: C07D405/12 , A61K31/4439 , C07D401/04 , C07D401/12 , C07D403/12
Abstract: The present invention relates to indole and indazole compounds of Formula (I) that activate 5′ adenosine monophosphate-activated protein kinase (AMPK). The invention also encompasses pharmaceutical compositions containing these compounds and methods for treating or preventing diseases, conditions, or disorders ameliorated by activation of AMPK.
Abstract translation: 本发明涉及活化5'腺苷单磷酸活化蛋白激酶（AMPK）的式（I）的吲哚和吲唑化合物。 本发明还包括含有这些化合物的药物组合物和用于治疗或预防通过AMPK活化改善的疾病，病症或障碍的方法。
-
公开(公告)号：US20150336958A1
公开(公告)日：2015-11-26
申请号：US14820884
申请日：2015-08-07
Applicant: PFIZER INC.
IPC: C07D471/10
CPC classification number: C07D471/10 , C07D519/00
Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof; wherein G is R1, R2 and R3 areas described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.
Abstract translation: 本发明提供式（I）化合物或其药学上可接受的盐; 其中G为本文所述的R1，R2和R3区; 其药物组合物; 以及其用于治疗通过抑制动物体内的乙酰辅酶A羧化酶调节的疾病，病症或病症的用途。
-
公开(公告)号：US20150112068A1
公开(公告)日：2015-04-23
申请号：US14593370
申请日：2015-01-09
Applicant: PFIZER INC.
IPC: C07D471/10
CPC classification number: C07D471/10 , C07D519/00
Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof; wherein G is R1, R2 and R3 areas described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.
-
公开(公告)号：US20150099782A1
公开(公告)日：2015-04-09
申请号：US14506752
申请日：2014-10-06
Applicant: PFIZER INC.
Inventor： Kevin Barry Bahnck , David James Edmonds , Kentaro Futatsugi , Esther Cheng Yin Lee , Alan Martin Mathiowetz , Elnaz Menhaji-Klotz , Robert Vernon Stanton
IPC: C07D401/14
CPC classification number: C07D401/14
Abstract: Provided herein are antagonists of prostaglandin EP3 receptor, processes to make said antagonists, and methods comprising administering said antagonists to a mammal in need thereof.
Abstract translation: 本文提供前列腺素EP3受体的拮抗剂，制备所述拮抗剂的方法，以及包括向有需要的哺乳动物施用所述拮抗剂的方法。
-
公开(公告)号：US20140323730A1
公开(公告)日：2014-10-30
申请号：US14325420
申请日：2014-07-08
Applicant: Pfizer Inc.
IPC: C07D471/10
CPC classification number: C07D471/10 , C07D519/00
Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof; wherein G is R1, R2 and R3 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.
Abstract translation: 本发明提供式（I）化合物或其药学上可接受的盐; 其中G为R 1，R 2和R 3如本文所述; 其药物组合物; 以及其用于治疗通过抑制动物体内的乙酰辅酶A羧化酶调节的疾病，病症或病症的用途。
-
-
-
-
-
-
-
-
-
Search Results
30
records
(took 0.039 seconds)
